Lebanova Hristina, Yanachkova Vesselina, Stoev Svetoslav
Department of Pharmaceutical Sciences and Social Pharmacy, Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria.
Research Institute, Medical University-Pleven, 5800 Pleven, Bulgaria.
Pharmacy (Basel). 2025 Jul 11;13(4):95. doi: 10.3390/pharmacy13040095.
Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in women of reproductive age, often requiring complex pharmacological management. The heterogeneity of the syndrome and the use of on- and off-label therapeutic agents-ranging from insulin sensitizers and ovulation inducers to oral contraceptives and herbal supplements-pose significant challenges, including adverse effects, drug interactions, and poor adherence. This narrative review explores the role of pharmacists in identifying and mitigating drug-related problems (DRPs) associated with PCOS therapy. Through thematic synthesis of the current literature, the study highlights common DRPs such as suboptimal drug selection, inappropriate dosing, prolonged therapy duration, and treatment-related safety concerns. It underscores the value of pharmacists' interventions in enhancing medication adherence, optimizing therapeutic regimens, providing patient education, and monitoring adverse events. A structured, patient-level pharmaceutical care model is proposed, emphasizing personalized assessment, interdisciplinary collaboration, and continuous follow-up. The integration of clinical pharmacists into PCOS care teams has the potential to improve treatment effectiveness, patient satisfaction, and long-term health outcomes. Pharmacists' contributions are especially critical given the widespread use of off-label therapies and supplements with variable evidence of benefit. Tailored pharmaceutical care can thus bridge the existing gaps in PCOS management and enhance the quality of life for the affected individuals.
多囊卵巢综合征(PCOS)是一种在育龄女性中普遍存在的内分泌紊乱疾病,通常需要复杂的药物治疗。该综合征的异质性以及使用标签内和标签外治疗药物(从胰岛素增敏剂、促排卵药到口服避孕药和草药补充剂)带来了重大挑战,包括不良反应、药物相互作用和依从性差等问题。本叙述性综述探讨了药剂师在识别和减轻与PCOS治疗相关的药物相关问题(DRP)方面的作用。通过对当前文献的主题综合分析,该研究突出了常见的DRP,如药物选择不当、剂量不合适、治疗时间延长以及与治疗相关的安全问题。它强调了药剂师干预在提高用药依从性、优化治疗方案、提供患者教育以及监测不良事件方面的价值。提出了一种结构化的、以患者为中心的药学服务模式,强调个性化评估、跨学科协作和持续随访。鉴于标签外疗法和补充剂的广泛使用以及益处证据不一,将临床药剂师纳入PCOS护理团队有可能提高治疗效果、患者满意度和长期健康结局。鉴于此,药剂师的贡献尤为关键。量身定制的药学服务因此可以弥合PCOS管理中现有的差距,并提高受影响个体的生活质量。